Balazs Halmos

Montefiore Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (88)

Year:

2026

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Thirteen studies were identified in the latest search of literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients with driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .

Year:

2026

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Six new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (35)

Alessandro Di Federico

University of Bologna

ITALY
View details

Yiyu Zou

associate professor

Albert Einstein College of Medicine

UNITED STATES
View details

Jorge Nieva

Professor of Clinical Medicine

University of Southern California

UNITED STATES
View details

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Deniz Demircioglu

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Jyoti D. Patel

Northwestern University

UNITED STATES
View details

Jarushka Naidoo

Honorary Senior Lecturer

Royal College of Surgeons in Ireland

IRELAND
View details

Pragnya Das

Cooper University Hospital

UNITED STATES
View details

Hirva Mamdani

Karmanos Cancer Institute

UNITED STATES
View details

Stephen Liu

Associate Professor

Georgetown University School of Medicine

UNITED STATES
View details

Joshua Reuss

Assistant Professor of Medicine

-

UNITED STATES
View details

Erin Schenk

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Daniel Starczynowski

Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Seshiru Nakazawa

Gunma University

JAPAN
View details

Haiying Cheng

Associate Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Toby C. Campbell

University of Wisconsin-Madison

UNITED STATES
View details

Ari VanderWalde

Global Head of Clinical Trials

-

UNITED STATES
View details

Lindsay LaFave

Assistant Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Varun Gupta

Staff Scientist

Albert Einstein College of Medicine

UNITED STATES
View details

Vineeth Sukrithan

Assistant Professor of Medicine

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Alexander Drilon

Thomas Jefferson University Hospital

UNITED STATES
View details

Misty Shields

Assistant Professor

Indiana State University

UNITED STATES
View details

Simone Sidoli

Associate Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Aaron Lisberg

University of California, Los Angeles

UNITED STATES
View details

Aditi Shastri

Albert Einstein College of Medicine

UNITED STATES
View details

Naoki Furuya

Ohio State University

UNITED STATES
View details

Ulrich Steidl

Albert Einstein College of Medicine

UNITED STATES
View details

Barliz Waissengrin

Assistant professor

Cedars-Sinai Medical Center

UNITED STATES
View details

William Feng

Dana-Farber Cancer Institute

UNITED STATES
View details

Lyudmila Bazhenova

University of California

UNITED STATES
View details

Hossein Borghaei

Professor and Chief, Thoracic Oncology

Fox Chase Cancer Center

UNITED STATES
View details

Nagla Abdel Karim

University of Virginia

UNITED STATES
View details

Benjamin Solomon

Professor

University of Melbourne

AUSTRALIA
View details

Srinivas Aluri

Research Assistant Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Dwight H. Owen

Ohio State University

UNITED STATES
View details